The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival
- 13 June 2019
- journal article
- research article
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 33 (9) , 681-688
Abstract
The primary aim of this study was to evaluate the volumetric therapy response via Ga-68 PSMA I&T PET/CT in patients treated with Lu-177 PSMA I&T therapy. The secondary purpose was to determine the impact of volumetric parameter responses to overall survival.Keywords
This publication has 26 references indexed in Scilit:
- Reproducibility of standardized uptake values of same-day randomized 68Ga-PSMA-11 PET/CT and PET/MR scans in recurrent prostate cancer patientsAnnals of Nuclear Medicine, 2018
- Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developmentsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapyJournal of Medical Radiation Sciences, 2017
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate CancerJournal of Nuclear Medicine, 2016
- Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0Radiology, 2016
- New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and TherapyClinical Cancer Research, 2016
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009